바이오모아 (BioMoa) — ADC · Antibody

8428프로그램 40FDA 승인

26오늘 방문

1,479누적 방문

7303갱신 대기 S–CData Tier S/A/B차세대 →Insight 1032HER2 breast 4683Antibody 2713CGT →Psoriasis →NSCLC 40FDA 승인

피드 Data Tier 차세대 Insight

최근 활동

RSS →

CGTBiologicstaleShanghai Zhongshan HospitalPhase 1

First dose group (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8, Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group))

HCC · HCC

#HCC#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 RECRUITING

CGTBiologicstalePeking University People's Hosp…Phase 2

CD5-targeted CAR-T cells (CD5-targeted CAR-T cells)

Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; T - Cell Lymphoma · Precursor T-Cell Lymphoblastic Leukemia-

#PrecursorT-CellLymphoblasticLeuk#CGT#Phase2#세포유전치료#CAR-T+3

임상시험 1상태 RECRUITING

ADCBiologicstaleDaiichi SankyoPhase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

Breast Cancer · Breast Cancer

#BreastCancer#ADC#Phase2#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

AntibodystalePfizerPhase 1

Maplirpacept (Maplirpacept)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase1#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleWashington University School of…Phase 2

Elrantamab (Elrantamab)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

CGTBiologicstaleBeijing Immunochina Medical Sci…Phase 1

IM21 CAR-T cells (IM21 CAR-T cells)

Multiple Myeloma · Multiple Myeloma

#MultipleMyeloma#CGT#Phase1#세포유전치료#CAR-T+2

임상시험 1상태 ACTIVE

CGTBiologicstaleSeoul National University Hospi…Phase 2

SNUH-CD19-CAR-T (SNUH-CD19-CAR-T)

Very High Risk Acute Lymphoblastic Leukemia; CD19 CAR-T Therapy · CD19

#CD19#CGT#Phase2#세포유전치료#CAR-T+4

임상시험 1상태 RECRUITING

AntibodystaleNovartisPhase 1

Cosentyx（Secukinumab ） (Cosentyx（Secukinumab ）)

Psoriasis · Psoriasis

#Psoriasis#Antibody#Phase1#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystalePeking Union Medical CollegePreclinical

Surgery combined with secukinumab (Surgery combined with secukinumab)

Hidradenitis Suppurativa (HS); Hidradenitis Suppurativa (Acne Inversa) · Hidradenitis Suppurativa (HS)

#HidradenitisSuppurativaHS#Antibody#Preclinical#항체#면역항체+3

임상시험 1상태 RECRUITING

AntibodystaleUniversity Hospital, GhentApproved

Proactive TDM-based dosing of ixekizumab (Proactive TDM-based dosing of ixekizumab)

Psoriasis Vulgaris · Psoriasis Vulgaris

#PsoriasisVulgaris#Antibody#Approved#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleUniversity Hospital, GhentApproved

Proactive TDM-based dosing of guselkumab (Proactive TDM-based dosing of guselkumab)

Psoriasis Vulgaris · Psoriasis Vulgaris

#PsoriasisVulgaris#Antibody#Approved#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleUniversity Hospital, GhentApproved

Proactive TDM-based dosing of secukinumab (Proactive TDM-based dosing of secukinumab)

Psoriasis Vulgaris · Psoriasis Vulgaris

#PsoriasisVulgaris#Antibody#Approved#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleTae Won KimPhase 2

durvalumab (Imfinzi, CKD-516 plus Durvalumab)

Colorectal Cancer; Solid Tumor · Colorectal Cancer

#ColorectalCancer#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 DISCONTINUED

ADCBiologicstaleInstitut CuriePhase 3

Endocrine therapy combined with the local treatment of FES-negative lesions (Endocrine therapy combined with the local treatment of FES-negative lesions)

Breast Carcinoma · Breast Carcinoma

#BreastCarcinoma#ADC#Phase3#항체약물접합체#antibody-drug-conjugate+1

임상시험 1상태 RECRUITING

AntibodystaleAstraZenecaPhase 1

durvalumab (Imfinzi, AZD9150, Durvalumab)

Advanced Solid Malignancies · Advanced Solid Malignancies

#AdvancedSolidMalignancies#Antibody#Phase1#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleInsel Gruppe AG, University Hos…Phase 2

durvalumab (Imfinzi, Gemcitabin, Cisplatin and Durvalumab)

Bile Duct Cancer · Bile Duct Cancer

#BileDuctCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleShanghai Cancer Hospital, ChinaPhase 2

durvalumab (Imfinzi, pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT)

Lung Cancer Stage IV，EGFR-mutant，TKI，PD-L1，SBRT · EGFR

#EGFR#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 ACTIVE

ADCBiologicstaleNorthwestern UniversityPhase 1

PI3K inhibitor BYL719 (PI3K inhibitor BYL719)

HER2-positive Breast Cancer; Recurrent Breast Cancer · HER2

#HER2#ADC#Phase1#항체약물접합체#antibody-drug-conjugate+3

효능 ORR 4%임상시험 1상태 ACTIVE

AntibodystaleTaizhou Mabtech Pharmaceutical …Phase 3

CMAB015 (CMAB015)

Psoriasis · Psoriasis

#Psoriasis#Antibody#Phase3#항체#면역항체+2

임상시험 1상태 ACTIVE

AntibodystaleRochePhase 1

durvalumab (Imfinzi, Obinutuzumab, naptumomab estafenatox and durvalumab)

ER+ Breast Cancer; Ovarian Cancer · HER2

#HER2#Antibody#Phase1#항체#면역항체+4

임상시험 1상태 RECRUITING

AntibodystaleNeoTX Therapeutics Ltd.Phase 1

durvalumab (Imfinzi, Naptumomab estafenatox and durvalumab)

ER+ Breast Cancer; Ovarian Cancer · HER2

#HER2#Antibody#Phase1#항체#면역항체+4

임상시험 1상태 RECRUITING

AntibodystaleI-Mab Biopharma US LimitedPhase 1

durvalumab (Imfinzi, TJ033721, TJ033721 (givastomig), durvalumab, chemotherapy, givastomig)

Solid Tumor; Advanced Cancer · Solid Tumor

#SolidTumor#Antibody#Phase1#항체#면역항체+3

임상시험 1상태 RECRUITING

AntibodystaleNordic Society of Gynaecologica…Phase 2

durvalumab (Imfinzi, Olaparib + durvalumab + UV1)

Ovarian Cancer · Ovarian Cancer

#OvarianCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 RECRUITING

AntibodystaleMedPacto, Inc.Phase 2

durvalumab (Imfinzi, TEW-7197, Vactosertib, Vactosertib(TEW-7197)/ Durvalumab)

Urothelial Carcinoma Recurrent; Advanced Urothelial Carcinoma · Urothelial Carcinoma Recurrent

#UrothelialCarcinomaRecurrent#Antibody#Phase2#항체#면역항체+3

임상시험 1상태 DISCONTINUED

AntibodystaleXin-Hua XuPhase 2

Sindillimab (Sindillimab)

Non-small Cell Lung Cancer · Non-small Cell Lung Cancer

#Non-smallCellLungCancer#Antibody#Phase2#항체#면역항체+2

임상시험 1상태 ACTIVE

126 / 142 페이지

← 이전 다음 →

전체 8,428개 프로그램 보기

갱신 기록 없음 · 14일 주기 · 방문 26 / 1,479

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

First dose group (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8, Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group))

CD5-targeted CAR-T cells (CD5-targeted CAR-T cells)

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

Maplirpacept (Maplirpacept)

Elrantamab (Elrantamab)

IM21 CAR-T cells (IM21 CAR-T cells)

SNUH-CD19-CAR-T (SNUH-CD19-CAR-T)

Cosentyx（Secukinumab ） (Cosentyx（Secukinumab ）)

Surgery combined with secukinumab (Surgery combined with secukinumab)

Proactive TDM-based dosing of ixekizumab (Proactive TDM-based dosing of ixekizumab)

Proactive TDM-based dosing of guselkumab (Proactive TDM-based dosing of guselkumab)

Proactive TDM-based dosing of secukinumab (Proactive TDM-based dosing of secukinumab)

durvalumab (Imfinzi, CKD-516 plus Durvalumab)

Endocrine therapy combined with the local treatment of FES-negative lesions (Endocrine therapy combined with the local treatment of FES-negative lesions)

durvalumab (Imfinzi, AZD9150, Durvalumab)

durvalumab (Imfinzi, Gemcitabin, Cisplatin and Durvalumab)

durvalumab (Imfinzi, pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT)

PI3K inhibitor BYL719 (PI3K inhibitor BYL719)

CMAB015 (CMAB015)

durvalumab (Imfinzi, Obinutuzumab, naptumomab estafenatox and durvalumab)

durvalumab (Imfinzi, Naptumomab estafenatox and durvalumab)

durvalumab (Imfinzi, TJ033721, TJ033721 (givastomig), durvalumab, chemotherapy, givastomig)

durvalumab (Imfinzi, Olaparib + durvalumab + UV1)

durvalumab (Imfinzi, TEW-7197, Vactosertib, Vactosertib(TEW-7197)/ Durvalumab)

Sindillimab (Sindillimab)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

First dose group (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8, Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group))

CD5-targeted CAR-T cells (CD5-targeted CAR-T cells)

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

Maplirpacept (Maplirpacept)

Elrantamab (Elrantamab)

IM21 CAR-T cells (IM21 CAR-T cells)

SNUH-CD19-CAR-T (SNUH-CD19-CAR-T)

Cosentyx（Secukinumab ） (Cosentyx（Secukinumab ）)

Surgery combined with secukinumab (Surgery combined with secukinumab)

Proactive TDM-based dosing of ixekizumab (Proactive TDM-based dosing of ixekizumab)

Proactive TDM-based dosing of guselkumab (Proactive TDM-based dosing of guselkumab)

Proactive TDM-based dosing of secukinumab (Proactive TDM-based dosing of secukinumab)

durvalumab (Imfinzi, CKD-516 plus Durvalumab)

Endocrine therapy combined with the local treatment of FES-negative lesions (Endocrine therapy combined with the local treatment of FES-negative lesions)

durvalumab (Imfinzi, AZD9150, Durvalumab)

durvalumab (Imfinzi, Gemcitabin, Cisplatin and Durvalumab)

durvalumab (Imfinzi, pemetrexed，cisplatin/carboplatin，bevacizumab，durvalumab，SBRT)

PI3K inhibitor BYL719 (PI3K inhibitor BYL719)

CMAB015 (CMAB015)

durvalumab (Imfinzi, Obinutuzumab, naptumomab estafenatox and durvalumab)

durvalumab (Imfinzi, Naptumomab estafenatox and durvalumab)

durvalumab (Imfinzi, TJ033721, TJ033721 (givastomig), durvalumab, chemotherapy, givastomig)

durvalumab (Imfinzi, Olaparib + durvalumab + UV1)

durvalumab (Imfinzi, TEW-7197, Vactosertib, Vactosertib(TEW-7197)/ Durvalumab)

Sindillimab (Sindillimab)

함께 비교하는 진짜 ADC · Antibody · CGT 데이터

추천 비교

최근 활동

빠른 검색 · 이슈 태그

실시간 이슈 · 검색

First dose group (Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8, Gene modified anti-IL1RAP Chimeric Antigen Receptor T Cells :1.0×10^8(First dose group))

CD5-targeted CAR-T cells (CD5-targeted CAR-T cells)

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201)

Maplirpacept (Maplirpacept)

Elrantamab (Elrantamab)

IM21 CAR-T cells (IM21 CAR-T cells)

SNUH-CD19-CAR-T (SNUH-CD19-CAR-T)

Cosentyx（Secukinumab ） (Cosentyx（Secukinumab ）)

Surgery combined with secukinumab (Surgery combined with secukinumab)

Proactive TDM-based dosing of ixekizumab (Proactive TDM-based dosing of ixekizumab)

Proactive TDM-based dosing of guselkumab (Proactive TDM-based dosing of guselkumab)

Proactive TDM-based dosing of secukinumab (Proactive TDM-based dosing of secukinumab)

durvalumab (Imfinzi, CKD-516 plus Durvalumab)

Endocrine therapy combined with the local treatment of FES-negative lesions (Endocrine therapy combined with the local treatment of FES-negative lesions)

durvalumab (Imfinzi, AZD9150, Durvalumab)

durvalumab (Imfinzi, Gemcitabin, Cisplatin and Durvalumab)